Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00089115

Public ClinicalTrials.gov record NCT00089115. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III, Randomized, Double Blind, Placebo-Controlled Trial of Favldand GM-CSF Versus Placebo and GM-CSF Following Rituximab in Subjects With Follicular B-Cell Non-Hodgkin's Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow and peripheral blood. It is not yet known whether combining rituximab and GM-CSF with vaccine therapy may cause a stronger immune response and kill more cancer cells. PURPOSE: This randomized phase III trial is studying giving rituximab and GM-CSF together with vaccine therapy and comparing it to giving rituximab and GM-CSF alone in treating patients with newly diagnosed, relapsed, or refractory B-cell non-Hodgkin's lymphoma.

Study identification

NCT ID
NCT00089115
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Favrille
Industry
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2004 (Type not available)
Primary completion
Not listed
Completion
Not listed
Last update posted
Aug 2, 2013

Started 2004

United States locations

U.S. sites
60
U.S. states
31
U.S. cities
52
Facility City State ZIP Site status
Comprehensive Cancer Center at University of Alabama at Birmingham Birmingham Alabama 35294 —
Mayo Clinic Scottsdale Scottsdale Arizona 85259 —
Tower Cancer Research Foundation Beverly Hills California 90211 —
Rebecca and John Moores UCSD Cancer Center La Jolla California 92093-0658 —
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center Los Angeles California 90048 —
USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California 90089 —
Hoag Cancer Center at Hoag Memorial Hospital Presbyterian Newport Beach California 92663 —
Kaiser Permanente Medical Center - Kaiser Foundation Hospital - San Diego San Diego California 92120 —
Sharp Memorial Hospital Cancer Center San Diego California 92123 —
UCSF Comprehensive Cancer Center San Francisco California 94143-0324 —
Stanford Cancer Center at Stanford University Medical Center Stanford California 94305 —
Kaiser Permanente Medical Center - Vallejo Vallejo California 94589 —
Rocky Mountain Cancer Centers - Denver Midtown Denver Colorado 80218 —
Medical Oncology Hematology Consultants, P.A. at Helen F. Graham Cancer Center Newark Delaware 19713-2055 —
Lombardi Cancer Center at Georgetown University Medical Center Washington D.C. District of Columbia 20007 —
Center for Hematology-Oncology - Boca Raton Boca Raton Florida 33486 —
University of Florida Health Science Center - Jacksonville Jacksonville Florida 32209 —
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Tampa Florida 33612-9497 —
North Idaho Cancer Center Coeur d'Alene Idaho 83814 —
Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago Illinois 60611 —
Rush University Medical Center Chicago Illinois 60612 —
Indiana University Cancer Center Indianapolis Indiana 46202 —
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center Kansas City Kansas 66160-7357 —
Markey Cancer Center at University of Kentucky Chandler Medical Center Lexington Kentucky 40536-0084 —
Ochsner Cancer Institute at Ochsner Clinic Foundation New Orleans Louisiana 70121 —
Greater Baltimore Medical Center Baltimore Maryland 21204-6881 —
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston Massachusetts 02115 —
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201-1379 —
Josephine Ford Cancer Center at Henry Ford Hospital Detroit Michigan 48202-2608 —
Mayo Clinic Cancer Center Rochester Minnesota 55905 —
Siteman Cancer Center at Barnes-Jewish Hospital St Louis Missouri 63110 —
Montana Cancer Specialists at Montana Cancer Center Missoula Montana 59802 —
New Mexico Cancer Center Albuquerque New Mexico 87109 —
North Shore University Hospital Manhasset New York 11030 —
Beth Israel Medical Center - Philipps Ambulatory Care Center New York New York 10003 —
Memorial Sloan-Kettering Cancer Center New York New York 10021 —
James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester New York 14642 —
Our Lady of Mercy Medical Center Comprehensive Cancer Center The Bronx New York 10466-2604 —
Comprehensive Cancer Center at Wake Forest University Winston-Salem North Carolina 27157-1082 —
Mid Dakota Clinic, P. C. Bismarck North Dakota 58502-5538 —
Roger Maris Cancer Center at MeritCare Hospital Fargo North Dakota 58122 —
Charles M. Barrett Cancer Center at University Hospital Cincinnati Ohio 45219 —
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University Cleveland Ohio 44106-5047 —
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195 —
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Columbus Ohio 43210-1240 —
Providence Cancer Center at Providence Portland Medical Center Portland Oregon 97213 —
Kaiser Permanente Medical Office - Interstate Medical Office Central Portland Oregon 97227 —
Cancer Institute at Oregon Health and Science University Portland Oregon 97239-3098 —
Geisinger Medical Center Danville Pennsylvania 17822-0001 —
Fox Chase-Temple Cancer Center Philadelphia Pennsylvania 19111-2497 —
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital Pittsburgh Pennsylvania 15224 —
Sarah Cannon Cancer Center at Centennial Medical Center Nashville Tennessee 37203 —
Baylor University Medical Center - Dallas Dallas Texas 75246 —
M.D. Anderson Cancer Center at University of Texas Houston Texas 77030-4009 —
Cancer Care Network of South Texas San Antonio Texas 78229 —
University of Virginia Cancer Center Charlottesville Virginia 22908 —
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Seattle Washington 98104 —
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima Washington 98902 —
University of Wisconsin Comprehensive Cancer Center Madison Wisconsin 53792-6164 —
Marshfield Clinic - Marshfield Center Marshfield Wisconsin 54449 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00089115, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 2, 2013 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00089115 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →